Inmune Bio, Inc. Terminates Material Agreement
Ticker: INMB · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $75,000,000, $10.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-agreement
Related Tickers: IBIO
TL;DR
IBIO terminated a big deal, details scarce.
AI Summary
On December 5, 2025, Inmune Bio, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it is classified under Item 1.02 of the 8-K form.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material agreement can signal underlying business issues or a shift in strategy, warranting closer examination.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- December 5, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — Commission File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Blvd. , Suite 640 , Boca Raton , Florida 33432 (address) — Address of Principal Executive Offices
- 561-710-0512 (phone_number) — Registrant's Telephone Number
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the name of the counterparty to the terminated agreement.
What is the effective date of the termination?
The earliest event reported, which is the termination of the material definitive agreement, occurred on December 5, 2025.
Under which item of the 8-K form is this termination reported?
This termination is reported under Item 1.02 of the 8-K form, which pertains to the termination of a material definitive agreement.
Does the filing provide any information on the financial or operational impact of this termination?
No, the provided excerpt of the filing does not contain information regarding the financial or operational impact of the termination.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-12-10 16:00:38
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $75,000,000 — ng an aggregate offering price of up to $75,000,000, from time to time through RBC and BTIG
- $10.5 million — , raising net proceeds of approximately $10.5 million. The description of the Sales Agreemen
Filing Documents
- ea0269071-8k_inmune.htm (8-K) — 24KB
- 0001213900-25-120067.txt ( ) — 185KB
- inmb-20251205.xsd (EX-101.SCH) — 3KB
- inmb-20251205_lab.xml (EX-101.LAB) — 33KB
- inmb-20251205_pre.xml (EX-101.PRE) — 22KB
- ea0269071-8k_inmune_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: December 10, 2025 By: /s/ David Moss David Moss Chief Executive Officer 2